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Summary
Loss of imprinting (LOI), commonly observed in human tumors, refers to loss of monoallelic gene regulation normally
conferred by parent-of-origin-specific DNA methylation. To test the function of LOI in tumorigenesis, we developed a
model by using transient demethylation to generate imprint-free mouse embryonic stem cells (IF-ES cells). Embryonic
fibroblasts derived from IF-ES cells (IF-MEFs) display TGFβ resistance and reduced p19 and p53 expression and form
tumors in SCID mice. IF-MEFs exhibit spontaneous immortalization and cooperate with H-Ras in cellular transformation.
Chimeric animals derived from IF-ES cells develop multiple tumors arising from the injected IF-ES cells within 12 months.
These data demonstrate that LOI alone can predispose cells to tumorigenesis and identify a pathway through which
immortality conferred by LOI lowers the threshold for transformation.S I G N I F I C A N C E
Loss of the DNA methylation associated with specific imprinted genes is a common feature of human cancers. However, it has not
been clear if a global loss of imprinting (LOI) in untransformed cells would predispose them to tumorigenesis. We now report evi-
dence to support a model in which LOI at key loci encoding tumor suppressors and oncogenes provides the first step toward tumor
formation by conferring cellular immortality. Subsequent genetic alterations, such as constitutive activation of a mitogenic signal,
would then provide the next step necessary for a fully transformed phenotype.Introduction
Cancer has traditionally been thought to be caused by a series
of genetic mutations in cancer susceptibility genes, which in-
clude oncogenes, tumor suppressor genes, and genes causing
genetic instability. Until recently, this rationale has remained
relatively unchallenged. However, it is now clear that epigenetic
changes (changes to the DNA maintained by cell division other
than alterations to the nucleotide sequence) play a critical role
during tumorigenesis (Feinberg and Tycko, 2004). The genome
of cancer cells is characterized by localized hypermethylation
in CpG islands, resulting in the silencing of tumor suppressor
gene expression (Baylin and Bestor, 2002). In addition, global
genomic and CpG island hypomethylation are associated with
both benign and malignant tumors (Feinberg and Vogelstein,
1983a; Gama-Sosa et al., 1983). Mechanistically, these epige-
netic changes are known to cause both oncogene activation
and chromosomal instability resulting in loss of heterozygosity
(Feinberg and Vogelstein, 1983b; Chen et al., 1998; Gaudet et
al., 2003).
Imprinted genes display a characteristic parent-of-origin-
specific DNA methylation pattern that results in only a singleCANCER CELL : OCTOBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIERallele being expressed (either the paternal or maternal allele).
DNA methylation that maintains the monoallelic expression of
imprinted genes is established during gametogenesis and is
important for fetal growth regulation and perinatal development
(Bartolomei, 2003; Reik and Walter, 2001). Although imprinting
persists in the adult, the requirements for proper imprinting in
the context of normal tissue homeostasis is not well under-
stood.
Loss of imprinting (LOI), either biallelic expression or com-
plete silencing of imprinted genes, has been implicated in the
progression of several tumors (Ogawa et al., 1993; Rainier et
al., 1993). For instance, aberrant biallelic expression of the In-
sulin-like growth factor-2 (IGF2) gene, a significant risk factor
for human colorectal carcinogenesis, is thought to promote tu-
morigenesis by inhibiting apoptosis (Cui et al., 2003). In addi-
tion PEG3, P57, and IGF2R all display LOI that leads to their
silencing in oligodendrogliomas, breast cancer, and hepatocel-
lular carcinomas, respectively (De Souza et al., 1997; Kobatake
et al., 2004; Trouillard et al., 2004). Although there is evidence
that LOI at the IGF2 locus promotes tumorigenesis in Beck-
with-Wiedemann syndrome (DeBaun et al., 2002), for the ma-
jority of human tumors it has not been clear if LOI plays aINC. DOI 10.1016/j.ccr.2005.09.007 275
A R T I C L Ecausal role in cancer or is merely a consequence of altered
epigenetic regulation in already transformed cells. Furthermore,
in all studies to date, the effects of LOI on cancer progression
have either been analyzed at single imprinted loci using associ-
ation studies in humans and mutational analysis in mice or
have examined the consequences of a global imbalance of ma-
ternal and paternal imprints in animals derived from partheno-
genetic or androgenetic cells, respectively (Hernandez et al.,
2003). Thus, the effect of genome-wide LOI on tumor formation
has not been addressed.
Here, we use conditional alleles of Dnmt1, which encodes a
DNA methyl transferase, to transiently remove all DNA methyl-
ation marks from the genome of embryonic stem (ES) cells.
Reactivation of Dnmt1 expression resulted in a restoration of
global DNA methylation but failed to remethylate imprinted
genes. From these imprint-free (IF) ES cells, we derived murine
embryonic fibroblasts (MEFs) and examined their growth char-
acteristics. The IF-MEFs displayed a number of characteristics
of transformed cells, including increased growth rate, immor-
tality, and resistance to growth inhibition by TGFβ. When in-
jected into severe combined immunodeficient (SCID) mice, the
IF-MEFs formed tumors with long latency. Overexpression of
oncogenic V12H-Ras in the IF-MEFs significantly shortened tu-
mor latency. Chimeric animals that were generated with the IF-
ES cells developed widespread tumors by 12 months of age,
with the cancers being derived from the IF-ES cells. Our find-
ings suggest a causal link between LOI and cancer and de-
monstrate that imprinting plays a critical tumor suppressor role
in the adult.
Results
Generation of IF- and CTL-ES cells
To investigate the role of LOI in the progression of cancer, we
took advantage of previous observations in which mouse ES
cells deficient in Dnmt1 (encoding an enzyme that maintains
global DNA methylation) were found to lack global DNA meth-
ylation, including the methylation associated with imprinting (Li
et al., 1993). Although loss of Dnmt1 through a conditional
knockout allele has no effect on ES cell viability, it is essential
in differentiated cells (Jackson-Grusby et al., 2001). Lethality
and global DNA methylation have been rescued following reex-
pression of a Dnmt1 cDNA in the Dnmt1 mutant ES cells
(Tucker et al., 1996b). However, because of the low Dnmt1 level
in the “rescued” cells, the genome was incompletely remethyl-
ated, resulting in abnormalities such as genomic instability
(Chen et al., 1998; Gaudet et al., 2003). To circumvent these
shortcomings, and to generate ES cells expressing normal and
properly regulated levels of Dnmt1, we devised an alternative
strategy in which Dnmt1 was first conditionally inactivated and
then reactivated by sequential exposure of the cells to the Cre
and flp recombinases. To do this, we constructed an inactive
Dnmt1 allele (2frt) by inserting a stop cassette flanked by two
Frt sites between the fourth and fifth exons of the Dnmt1 gene.
This mutant allele is revertible and becomes reactivated follow-
ing Flp-mediated recombination (Figure 1A; Figure S1 in the
Supplemental Data available with this article online). Mice car-
rying the 2frt allele were generated by injection of targeted ES
cells into mouse blastocysts, and the subsequent animals were
bred to the Dnmt1 2lox (Jackson-Grusby et al., 2001) and a
ROSA26 Flp reporter allele (Possemato et al., 2002). ES cell276Figure 1. Generation of IF- and CTL-ES cells
A: Schematic representation of the steps used to create the IF-ES cells (for
specific alleles and the status of global genomic methylation at each
stage, see Figure S1). CTL-ES cells were generated by reverse exposure to
the recombinases.
B: Genomic Southern blot analysis confirming the recombined DNMT1 al-
leles. Lane 1, wild-type Dnmt1; lane 2, 2loxp/2frt Dnmt1; lane 3, 1loxp/2frt
Dnmt1; lane 4, 1loxp/1frt Dnmt1.lines containing the Dnmt1 conditional 2lox and Dnmt1 2frt al-
leles and the Flp β-geo reporter allele were derived from these
animals (Figure 1A). When the 2lox/2frt ES cells were trans-
fected with a Cre plasmid, deletion of exons 4 and 5 created
the null Dnmt1 1lox allele, resulting in Dnmt1 deficiency (Figure
1B). Consistent with this, the 1lox/2frt cells displayed global
genome demethylation as demonstrated by Southern blot
analysis of centromeric regions, LINE, and IAP elements (Fig-
ure S1). The demethylated cells were then transfected with a
Flpe plasmid, causing the stop cassette to be excised (2frt/
1frt), the Dnmt1 allele to be reactivated, and genome methyla-
tion to be restored (Figure 1A; Figure S1; these cells are herein
referred to as “IF-ES cells”) (Buchholz et al., 1998). To serve as
a control, we transfected 2lox/2frt ES cells with Flpe first and
Cre second, a manipulation that maintains Dnmt1 activity at
each step and has no effect on genomic methylation level and
imprinting (referred to as “CTL-ES cells”) (Figure 1A).
Expression and methylation of IF- and CTL-MEFs
To confirm that our strategy had successfully erased imprint-
ing, we examined the methylation status of selected imprinted
genes in IF-ES cells and MEFs. To generate the MEFs, wild-
type blastocysts were injected with either IF- or CTL-ES cells,
and fibroblasts were isolated from E13.5 chimeras using G418
resistance to select for ES cell-derived MEFs. As assessed by
Southern blot analysis, the restoration of normal global methyl-
ation was maintained in the MEFs (Figures S1Ca–S1Cc). LOI
at the Igf2r, Snrpn, Peg3, and Igf2 loci was assessed by meth-
ylation-sensitive Southern blotting and COBRA analysis (XiongCANCER CELL : OCTOBER 2005
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Snrpn, and Peg3 was found in the CTL-ES cells and CTL-
MEFs, these genes lacked methylation in IF-ES cells and IF-
MEFs, consistent with LOI. In contrast, COBRA analysis re-
vealed that the differentially methylated region (DMR) of the
Igf2-H19 locus, a regulatory element that controls expression
of H19 and Igf2, was variably methylated in IF-ES cells and IF-
MEFs (Figure 2D). Although this result was contrary to expecta-
tion in our model, it was not surprising, since the Igf2-H19
DMR is highly susceptible to de novo methylation when the
methylation status of the genome has been altered (Baqir and
Smith, 2003; Biniszkiewicz et al., 2002; Chen et al., 1998;
Tucker et al., 1996b), whereas the methylation status of other
imprinted regions is more stable. Loss of the DNA methylation
associated with imprinting is expected to either erase or result
in biallelic expression of imprinted genes, depending on whether
the methylation of the respective imprinting box or DMR has a
positive or negative effect on transcription (Reik and Walter,
2001). To assess the effect of LOI on gene expression, we
examined the gene expression profiles of IF-MEFs and CTL-
MEFs using microarrays. This analysis revealed a tight cluster-
ing for most genes, indicating that there was very little differ-
ence in expression patterns between the two populations
(Pearson coefficient r = 0.9919) (Figure 2A). However, the ex-
pression of a small number of genes, mostly corresponding to
known imprinted genes, was altered (Figure 2B). The remaining
genes were known or likely downstream targets of imprinted
genes (data not shown), although we cannot rule out the possi-Figure 2. Characterization of IF- and CTL-MEFs
A: Characterization of IF- and CTL-MEFs by
microarray analysis.
B: Selected imprinted genes that are up- or
downregulated in IF-MEFs by microarray analy-
sis. p values: impact, 0.118; Plagl1, 0.040; Sgce,
0.118; Ndn, 0.069; Peg3, 0.383; Igf2r, 0.145;
Grb10/Meg1, 0.128; Ctgf, 0.002; Zim1, 0.228;
Thrombospondin, 0.0005.
C: Confirmation of the expression of selected
imprinted genes by Northern blot and RT-PCR
analysis. Lanes 1 and 2, CTL-MEFs; lanes 3, 4, 5,
and 6, IF-MEFs.
D: Methylation status of imprinted genes in CTL-
and IF-MEFs. Carried out by methylation-sensi-
tive Southern blot analysis for Igf2r and COBRA
analysis for Igf2, Snrpn, and Peg3.CANCER CELL : OCTOBER 2005bility that some represent non-imprint-related genes indepen-
dently affected by our demethylation/remethylation strategy. In
agreement with our finding that the Igf2-H19 DMR was variably
methylated, we found that the level of Igf2 was ~2-fold higher
and that there was no H19 expression in two of four IF-MEF
samples as compared to CTL-MEFs, and the other two IF-
MEFs were unchanged relative to the CTL-MEFs. To validate
the microarray data, expression of Meg1/Grb10, Igf2r, Igf2,
H19, Peg5, Peg1, Peg3, and p57 was examined in the IF- and
CTL-MEFs by Northern blot analysis and RT-PCR, as de-
scribed in the Experimental Procedures (Figure 2C). This analy-
sis confirmed that the IF-MEFs were negative for Igf2r, Meg1/
Grb10, and p57 and variable for H19 but displayed increased
levels of Peg3, Peg5, and variable Igf2 compared to CTL-
MEFs. Our findings suggest that the strategy of conditionally
inactivating and then reactivating Dnmt1 successfully erased
the methylation associated with imprinting, but not global ge-
nome methylation, resulting in widespread alterations in the ex-
pression of imprinted genes.
Altered growth properties of IF-MEFs
Many imprinted genes, such as Igf2 and Grb10/Meg1, have
been implicated in embryonic growth control (Reik and Walter,
2001). We therefore examined whether IF-MEFs displayed al-
tered growth properties compared to CTL-MEFs. To analyze
the cell cycle in the MEFs, DNA content was measured by flow
cytometry. The majority (~70%) of the CTL-MEFs were in the
G phase of the cell cycle, with approximately 13% and 17%277
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same culture conditions, the IF-MEFs displayed a higher mi-
totic index with a lower proportion of cells in the G1 (46%) and
S phases (7%) and a pronounced increase in the proportion of
cells in G2/M (47%) (Figure 3A). To determine if this altered cell
cycle profile was indicative of altered growth, we counted theFigure 3. Growth characteristics and immortalization of IF-MEFs
A: Cell cycle analysis of IF- and CTL-MEFs by flow cytometry. A representa-
tive example of propidium iodide-stained MEFs is shown for both IF and
CTL. The three arrows indicate the peaks that represent cells in G1, S, and
G2/M phase of the cell cycle, respectively. Below each graph is the quanti-
fication of cells in each stage of the cell cycle.
B: Growth rate of IF- and CTL-MEFs. The graph shows the faster growth rate
of IF-MEFs (9.3 × 104 cells/day) compared to CTL-MEFs (5.7 × 104 cells/day)
over a period of 8 days. Day 1: IF-MEFs, 149.5 ± 4.5; CTL-MEFs, 84.5 ± 6.2.
Day 2: IF-MEFs, 216 ± 4.1; CTL-MEFs, 105 ± 2.3. Day 3: IF-MEFs, 259 ± 7.1; CTL-
MEFs, 169.5 ± 2.9. Day 4: IF-MEFs, 331 ± 8.7; CTL-MEFs, 242.5 ± 7.7. Day 5:
IF-MEFs, 432.5 ± 4.7; CTL-MEFs, 301 ± 12.5. Day 6: IF-MEFs, 511.5 ± 10.02; CTL-
MEFs, 374 ± 17.1. Day 7: IF-MEFs, 622.5 ± 29.3; CTL-MEFs, 430 ± 18.1. Day 8:
IF-MEFs, 712.5 ± 46.6; CTL-MEFs, 486 ± 6.8.
C: Lack of response of IF-MEFs to the growth-inhibitory cytokine TGFβ. Day
1: IF-MEFs, 153 ± 5.3; CTL-MEFs, 81 ± 5.1; IF-MEFs + TGFβ, 150.5 ± 7.2; CTL-
MEFs + TGFβ, 86.5 ± 4.1. Day 2: IF-MEFs, 219 ± 4.11; CTL-MEFs, 107 ± 2.7; IF-
MEFs + TGFβ, 227 ± 3.8; CTL-MEFs + TGFβ, 114 ± 1.6. Day 3: IF-MEFs, 307 ±
6.9; CTL-MEFs, 153.8 ± 3.7; IF-MEFs + TGFβ, 351.5 ± 2.9; CTL-MEFs + TGFβ,
125.5 ± 4.1. Day 4: IF-MEFs, 397.4 ± 8.1; CTL-MEFs, 219 ± 7.1; IF-MEFs + TGFβ,
408.1 ± 5.5; CTL-MEFs + TGFβ, 117 ± 4.0. Day 5: IF-MEFs, 462.4 ± 4.7; CTL-
MEFs, 273 ± 10.3; IF-MEFs + TGFβ, 502 ± 4.4; CTL-MEFs + TGFβ, 146.9 ± 7.4.
D: IF-MEFs are immortal. Immortalization was determined by accumulated
number of population doublings over continued passages.
E: Western blotting analysis of cell cycle markers of CTL-MEFS and IF-MEFS
at increasing passages.278total number of IF- and CTL-MEFs during an 8 day interval
and calculated the growth rate during the exponential phase of
proliferation (2–4 days after plating; Figure 3B). The viability of
the exponentially growing cells was approximately 95% as as-
sessed by trypan blue dye exclusion. This analysis showed that
the IF-MEFs grew significantly faster than the control fibro-
blasts (Figure 3B), consistent with a shortened cell cycle.
Microarray analysis revealed the downregulation in IF-MEFs
of Igf2r, Tsp1, and p57 (Figure 2B), three genes known to posi-
tively regulate transforming growth factor-β (TGFβ) activation
and signaling. These gene expression changes coupled with
the increased growth rates in IF-MEFs suggested a potential
inability of IF-MEFs to respond to TGFβ, a pleiotropic cytokine
that inhibits the growth of a diverse range of cell types (Roberts
and Wakefield, 2003). To investigate whether LOI altered the
ability of MEFs to respond to TGFβ growth inhibition, we ex-
posed IF- and CTL-MEFs to TGFβ (0.1 ng/ml) 24 hr after plat-
ing. Within 48 hr, the CTL-MEFs had undergone growth arrest
(Figure 3C), whereas the IF-MEFs continued to proliferate nor-
mally (Figure 3C). These results suggest that IF-MEFs were no
longer responsive to the growth-inhibitory effects of TGFβ, a
property shared by malignant cells.
Immortalization and transformation of IF-MEFs
Wild-type MEFs have a limited life span in cell culture and
eventually undergo senescence. To determine the life span of
the IF-MEFs, we used the 3T3 protocol (Todaro and Green,
1963), which involves continuous passaging of the cells. By
passage 8, CTL-MEFs had undergone senescence and ap-
peared as large, flat, nondividing cells. In contrast, IF-MEFs
appeared to be spontaneously immortalized, as they main-
tained a constant proliferation rate and grew for at least 20
passages without showing any indication of undergoing senes-
cence (Figure 3D). Among many of the changes associated
with cellular senescence in culture is the increased expression
of cell cycle regulators, such as p16INK4A and p14/p19ARF, that
are thought to be critical in inducing permanent G0/G1 arrest
(Kamijo et al., 1997; Stein and Dulic, 1998). Figure 3A shows
that the level of p16INK4A increased in later passages of IF-
MEFs, comparable to that in CTL-MEFs. The p21CIP1 cell cycle
inhibitor has been shown to have a similar function as p16INK4A
in senescing human cells, although its role in mouse cells is
less clear (Brown et al., 1997; Pantoja and Serrano, 1999). Like
p16INK4A, the levels of p21CIP1 remained constant or increased
in the late passages of IF-MEFs (Figure 3E). In contrast, the
level of p19ARF did not increase in later passages of IF-MEFs
and was significantly less than in CTL-MEFs (Figure 3E). Be-
cause p14/p19ARF is known to bind to and sequester MDM2
and to inhibit the MDM2-dependent degradation of p53 (Sherr
and Weber, 2000), we examined the level of p53 in early- and
late-passage IF-MEFs. In early passages, p53 was present, but
as expected from the decreased level of p19ARF, p53 expres-
sion decreased significantly at later passages (Figure 3E).
Immortalization is an essential prerequisite for malignant
transformation in mammals (Hahn and Weinberg, 2002). There-
fore, we tested the transformation potential of IF-MEFs using
the classic foci formation assay. This assay involves the main-
tenance of confluent cells over a 3 week period without pas-
saging. In the rare incidence that a cell becomes transformed,
it escapes quiescence and forms a dense outgrowth known as
a focus. When CTL-MEFs were grown under these conditions,CANCER CELL : OCTOBER 2005
A R T I C L EFigure 4. Transformation of IF-MEFs
A: Spontaneous transformation of IF-MEFs mea-
sured by foci assay. IF-MEFs, 34.9 ± 2.4; CTL-MEFs,
1.3 ± 0.6; CTL-Igf2, 6.1 ± 1.5; CTL-Vector, 1.0 ±
0.93.
B: Representative plate demonstrating the
spontaneous transformation present in IF-MEF
foci assay.
C: IF-MEFs infected with V12-H-Ras (IF-Ras) show
altered morphology when compared to IF-MEFs
(IF) alone.
D: IF-Ras-MEFs grow at a significantly faster rate
than IF-MEFs.
E: Representative plate demonstrating sponta-
neous transformation in the low-density foci as-
say comparing IF, IF-LgT, and IF-Ras.1.3 ± 0.6 foci were found per plate (Figure 4A [CTL] and Figure
4B [CTL]). In contrast, IF-MEFs formed approximately 35 ± 2.4
foci (Figure 4A [IF] and Figure 4B [IF]), consistent with LOI pre-
disposing the IF-MEFs to spontaneous transformation.
Igf2 is an imprinted gene that often exhibits LOI and aberrant
biallelic expression in human tumors (Cui et al., 2003). To deter-
mine if biallelic expression of Igf2 was solely responsible for
the immortality and the increased rate of spontaneous trans-
formation of the IF-MEFs, we overexpressed Igf2 in CTL-MEFs
following retrovirus-mediated transduction. While Igf2 overex-
pression in CTL-MEFs led to an increased growth rate, it only
led to immortalization after extensive passaging as previously
reported (data not shown and Hernandez et al., 2003). In the
foci formation assay, Igf2-infected CTL-MEFs (at low passage
number) formed approximately 6-fold more foci than vector-
only-infected CTL-MEFs (6.1 ± 1.5 and 1 ± 0.9 foci, respec-
tively) but failed to induce the level of spontaneous transforma-
tion observed with IF-MEFs (Figure 4A). These data combined
with the Northern and microarray analysis suggest that the
variable expression levels of Igf2 contribute to the ability of the
cells to spontaneously transform. However, LOI of additional
genes is needed to achieve the full extent of immortalization
and transformation seen in IF-MEFs.
Forced overexpression of the oncogenes SV40 Large T anti-
gen (LgT) and a constitutively active growth signal, such as
that provided by V12H-Ras, in wild-type MEFs is sufficient to
cause cellular transformation. However, MEFs expressing
either oncogene alone will not become transformed, but in-
stead are either immortalized by LgT or are induced to undergo
senescence by V12 H-Ras (Hahn and Weinberg, 2002). Given
that the IF-MEFs displayed a greater potential for spontaneous
transformation, we asked whether the effect of LOI could re-
place the function of either LgT or active H-Ras in this process.CANCER CELL : OCTOBER 2005IF- and CTL-MEFs were infected with a LgT retroviral vector or
an empty vector, and drug selection was used to select for
transduced cells. The cells were plated at low density, and fo-
cus formation was assessed after a 14 day culture period. As
expected, LgT-infected CTL-MEFs formed a greater number of
foci as compared to the vector-only CTL-MEFs, similar to pre-
vious reports. Although the vector-only-infected IF-MEFs
formed more foci than the respective CTL-MEFs, no further
increase in foci numbers was observed in the LgT-infected IF-
MEFs (data not shown). Thus, LOI and LgT expression do not
cooperate in cellular transformation.
To ask whether LOI can replace the function of LgT and co-
operate with activated H-Ras, we examined the effect of V12H-
Ras expression on transformation frequency in IF-MEFs. CTL-
and IF-MEFs were infected with either a V12H-Ras or an empty
retrovirus vector. Expression of V12H-Ras in CTL-MEFs in-
duced an immediate inhibition of cell growth and quiescence
after passaging (data not shown), consistent with previous
studies (Serrano et al., 1997). In contrast, IF-MEFs infected
with V12H-Ras lost contact inhibition, exhibited a significant
change in morphology, and continued to proliferate at a signifi-
cantly higher rate than the vector-only control IF-MEFs (Figures
4C and 4D). In the focus formation assay, the V12H-Ras-
infected IF-MEFs displayed a massive increase in focus forma-
tion compared to vector-only-infected IF-MEFs (Figure 4E).
These results indicate that LOI cooperates with V12H-Ras to
fully transform MEFs.
Tumor formation
The tumorigenic potential of cells was tested in vivo by subcu-
taneous injection into SCID mice, which lack mature lympho-
cytes. In this assay, fully transformed cells will form tumors
beneath the skin at the site of injection. Using this assay, we279
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fected with either LgT or empty vector and IF-MEFs infected
with V12H-Ras. No tumors were found in SCID mice after 4–5
months following injection with CTL-MEFs (0/7) or LgT-infected
CTL-MEFs (0/7). Tumors were observed in SCID mice injected
with IF-MEFs (2/6) or LgT-infected IF-MEFs (2/6) after 5
months. In contrast, all SCID mice injected with V12H-Ras-
infected IF-MEFs (7/7) formed large fibrosarcomas within 14
days postinjection (Table 1). These findings are consistent with
cooperation between LOI and oncogenic Ras to induce a fully
transformed phenotype in MEFs. It should be noted that, due
to the senescence that occurred in V12H-Ras-infected CTL-
MEFs, there were insufficient cells to perform the tumor forma-
tion assay in SCID mice.
To further examine the role LOI plays in oncogenesis in vivo,
we created chimeric mice using IF- and CTL-ES cell lines
(using two independently derived ES cell lines for each condi-
tion). The level of chimerism contributed by the IF-ES cells
ranged from 5% to 20% in the adults, whereas CTL-ES cells
contributed up to 100%, as judged by coat color. Chimeras
were sacrificed at 9, 12, and 18 months of age, and their tis-
sues were examined histologically for abnormalities. Strikingly,
about half of the IF chimeras at 9 months of age (n = 3/5) and
all of the chimeras at 12 and 18 months of age showed the
presence of hepatocellular tumors and intestinal adenomas
(Table 2; Figures 5A–5E). The hepatocellular carcinomas, and
in some cases adenomas, averaged approximately 5 × 6 mm
in size (n = 6; data not shown) by 18 months of age. Other
cancers were also observed; for instance, in one IF chimera
the normal architecture of the testis was disrupted by a prolif-
eration of homogenous cells that was consistent with testicularTable 1. Incidence of MEF-derived fibrosarcomas in SCID mice
MEFs SCID mouse fibrosarcomas
8–12 days 4–5 months
CTL 0/6 0/6
CTL + LgT 0/6 0/6
IF 0/6 2/6
IF + LgT 0/6 2/6
IF + Ras 7/7 N/A
MEFs (2 × 106) were injected into three independent sites, and growth of tumors
was assessed after the defined time point.Table 2. The incidence of tumors in IF chimeras and after germline transmission
9 12 18 24
IF tumor incidence months months months months
Hepatocellular carcinomas 4/5 7/7 4/4
Intestinal adenomas/carcinomas 3/5 3/3a 4/4
Testicular seminoma 0/5 0/7 1/4
Lymphoma 0/5 1/7 0/4
Leukemia 0/5 1/7 0/4
Tumor incidence after germline transmission
Control 0/3 1/2
IF 0/4 0/4
aThree animals displayed large tumors obstructing the intestine; thorough ex-
aminations for smaller tumors in the remaining four animals were not performed.280Figure 5. Histological and expression analysis of IF tumors
Histological analysis of tumor formation in IF chimeras stained with H&E.
A: Sections of an IF hepatocellular carcinoma/adenoma. B–E: Intestinal
adenoma/carcinoma (B), lymphoma (C), chronic myeloid-like leukemia
(D), testicular seminoma (E). Fa: Genomic PCR to detect the presence of
the IF neomycin marker gene. Lane 1, BDFI wild-type host blastocyst; lane
2, hepatocellular tumor 1; lane 3, hepatocellular tumor 2; lane 4, hepato-
cellular tumor 3; lane 5, testicular seminoma; lane 6, intestinal adenoma;
lane 7, chronic myeloid-like leukemia; lane 8, lymphoma. Fb: RT-PCR ex-
pression analysis of selected imprinted genes in IF tumors. Lane 1, hepato-
cellular carcinoma; lane 2, testicular seminoma; lane 3, chronic myeloid-
like leukemia; lane 4, lymphoma; lane 5, wild-type liver; lane 6, wild-type
testis; lane 7, wild-type bone marrow; lane 8, wild-type spleen. G: Methyla-
tion status of selected imprinted genes in IF tumors by COBRA (Igf2) and
methylation-sensitive Southern blotting (Igf2r) analysis. Lane 1, hepatocel-
lular carcinoma; lane 2, intestinal adenoma; lane 3, testicular seminoma;
lane 4, chronic myeloid-like leukemia; lane 5, lymphoma; lane 6, wild-type
liver; lane 7, wild-type intestine; lane 8, wild-type testes; lane 9, wild-type
spleen; lane 10, wild-type bone marrow.seminoma (Figure 5E). Another IF chimera displayed spleno-
megaly, and histological analysis of the bone marrow revealed
a phenotype consistent with a leukemia (Figure 5D). In a 12-
month-old IF chimera, a large tumor with histology consistent
with lymphoma was isolated (Figure 5C). In contrast to these
results, control chimeras appeared healthy at all time points
and when sacrificed at 24 months of age displayed no tumors
(n = 6/6; up to 100% chimerism assessed by coat color contri-
bution).
To confirm that the cancers in the IF chimeras were derivedCANCER CELL : OCTOBER 2005
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by PCR for the presence of the neo fragment of the β-geo gene
contained in the IF-ES cells but not in the BDF1 host tissue.
The neo gene was amplified from all of the tumors examined,
consistent with an IF-ES cell origin for these neoplasms (Figure
5Fa). Taken together, tumorigenic potential of both IF-ES chi-
meras and IF-MEFs provides strong evidence that LOI pro-
motes transformation both in vitro and in vivo.
In humans, the imprinted genes p57, Igf2r, and Igf2 have
been implicated in the tumorigenesis of multiple cancers
(Feinberg and Tycko, 2004; Mills et al., 1998). We therefore ex-
amined the expression of these genes in tumors from the IF
chimeras. Similar to our results in IF-ES cells and IF-MEFs,
transcripts for p57 and Igf2r were absent in the tumors (Figure
5Fb, Igf2r, p57, lanes 1–4), whereas variable levels of Igf2 ex-
pression was found (Figure 5Fb, Igf2, lanes 1–4). In agreement
with our findings in IF-MEFs (Figure 1D), the tumors displayed
methylation of the Igf2-H19 locus (Figure 5G, Igf2, lanes 1–5).
These results indicate that the tumors observed in the chime-
ras display a loss of transcripts for the putative tumor suppres-
sors p57 and Igf2r and variable expression levels of the Igf2
oncogene, similar to that observed in the parental IF-ES cells
and IF-MEFs.
No tumors after germline transmission
Imprinted genomic methylation is established during gameto-
genesis (Tucker et al., 1996a), predicting that the breeding of
adult IF chimeras should “reset” the methylation state and re-
sult in progeny with normal imprinting. To test whether restora-
tion of normal imprinting would revert the tumorigenic phe-
notype, consistent with an epigenetic basis for these cancers,
IF-chimeric mice from the two independently derived IF-ES
and CTL-ES cells were crossed to C57B6 mice. Progeny inher-
iting the ES cell-derived genome, as determined by coat color,
were aged and examined for tumors at autopsy. Careful histo-
logical analyses failed to detect tumors at 18 or 24 months of
age (n = 0/8) with the exception of a single lung adenoma de-
tected at 24 months of age (n = 1/5) in a CTL mouse (Table 2).
Due to the age of this animal, this is most likely a spontaneous
tumor and not caused by genetic manipulation of the parental
ES cell line. The reversibility of the tumorigenic potential of IF
cells following germline passage supports the epigenetic basis
of these cancers and argues that tumor formation in the IF chi-
meras was not due to an oncogenic mutation incurred during
the culturing of the ES cells.
Discussion
It has been known for some time that altered DNA methylation
is associated with both benign and malignant tumor states.
Considerable attention has focused on the effect of global hy-
po- or hypermethylation of DNA in tumors, whereas less is
known about the importance of imprinting during cancer pro-
gression. The goals of this study were to engineer mice with
global LOI and then examine the involvement of imprinting in
tumorigenesis. By sequentially eliminating and then reestab-
lishing Dnmt1 expression in ES cells, we generated cells that
possessed normal global DNA methylation but lacked the
methylation associated with imprinting (with the exception of
the Igf2/H19 locus). Gene expression analyses confirmed the
success of our approach, with imprinted genes being eitherCANCER CELL : OCTOBER 2005silenced or upregulated ~2-fold in IF-MEFs compared with
control cells. An analysis of the growth and cell cycle charac-
teristics of IF-MEFs revealed that LOI conferred a number of
characteristics possessed by transformed cells, including a
higher growth rate, a shortened cell cycle time, cellular immor-
tality, resistance to TGFβ, and foci formation on a confluent
monolayer. Consistent with this, IF-MEFs formed tumors in
SCID mice, and more significantly, adult chimeric mice derived
from IF-ES cells developed tumors in multiple tissues. These
data demonstrate that, in addition to regulating normal embry-
onic growth, imprinting plays a much wider role in tissue ho-
meostasis by providing an essential tumor suppressor function
in the adult.
Previous studies have implicated altered imprinting at the
Igf2/H19 locus with cancer formation. In the case of Wilms tu-
mors in the rare Beckwith-Wiedemann syndrome, specific loss
of normal imprinting on the maternal H19 allele leads to biallelic
expression of IGF2 expression and is thought increase the
number of premalignant nephrogenic precursors (Okamoto et
al., 1997; Ravenel et al., 2001). In recent mouse studies, it was
shown that the number of intestinal tumors that form in Apc+/−
mutant mice was increased when Igf2 was biallelically ex-
pressed (Sakatani et al., 2005). These studies suggested that
a loss of normal imprinting at the Igf2/H19 locus contributes to
Wilms tumors and APC-induced intestinal tumors. However, it
is unlikely that deregulated Igf2 expression was solely respon-
sible for the transformed phenotype observed in IF-MEFs. In
our study, the Igf2/H19 DMR was variably de novo methylated
following reexpression of Dnmt1. This was an expected finding
because Igf2/H19 DMR, unlike other imprinted loci, has been
shown to be highly susceptible to de novo methylation during
cancer progression (Feinberg and Tycko, 2004), following reac-
tivation of high levels of Dnmt1 in Dnmt1−/− mutant cells (Bin-
iszkiewicz et al., 2002), and during in vitro cultivation of preim-
plantation embryos (Latham et al., 1994; Mann et al., 2004). As
a result of stochastic methylation at the Igf2/H19 DMR in both
the IF-MEFs and tumors, the expression of Igf2 (and H19) was
variable (ranging from normal to approximately biallelic levels
in the IF-MEFs). Therefore, it is unlikely that the enhanced tu-
morigenic potential of cells with LOI can be solely attributed
to altered expression of Igf2. Consistent with this, reactivating
monoallelic expression of Igf2r, which functions in the inactiva-
tion of IGF2, only slightly reduces the level of spontaneous
transformation of IF-MEFs (T.M.H. and R.J., unpublished data).
Similarly, overexpression of Igf2 in CTL-MEFs was not suffi-
cient to induce the high rate of spontaneous transformation
that was observed with IF-MEFs at low passage number (4–6),
although it led to an increased growth rate. We note that, at
higher passage numbers (>15), MEFs forced to overexpress
Igf2 undergo spontaneous transformation, which is likely the
result of secondary mutations that accrue during extensive
passaging (Hernandez et al., 2003). Based on these observa-
tions, we conclude that imprinted loci other than Igf2/H19 and
Igf2r are primarily responsible for the altered growth character-
istics and transformed phenotype of cells with LOI.
Immortalization is an essential prerequisite for the formation
of a tumor cell, as the introduction of an oncogene into a mam-
malian cell that is not immortalized will induce senescence or
apoptosis due to the activation of antineoplastic defense
mechanisms (Hahn and Weinberg, 2002). It is for this reason
that pairs of cooperating oncogenic mutations are needed to281
A R T I C L Etransform mouse cells, as the second oncogene is usually re-
quired to neutralize the protective pathways triggered by the
first oncogene. For instance, overexpression of oncogenic
V12H-Ras alone in MEFs leads to an upregulation of Arf and
premature growth arrest. Senescence can be avoided in these
cells by inhibiting the Arf-p53 pathway (Serrano et al., 1997).
Similarly, our data suggest that LOI confers immortality to
MEFs by inactivating the Arf-p53 pathway. Western blot analy-
sis revealed a significant decrease in the levels of p19Arf and
p53 in IF-MEFs. Consistent with this, overexpression of LgT in
IF-MEFs, which binds to and inactivates p53, did not enhance
tumor formation in the SCID assay. In contrast, overexpression
of V12H-Ras in IF-MEFs failed to induce growth arrest and in-
stead cooperated with LOI to induce tumors with short latency
in SCID mice. Given the role of Arf in protecting p53 from
MDM2-dependent degradation, it is possible that the reduction
in p53 in IF-MEFs results indirectly from a loss of Arf. At pre-
sent, the imprinted gene(s) responsible for the reduction in Arf
and p53 protein levels are unknown, and further study is re-
quired for their identification.
Deregulated TGFβ signaling is a common feature of malig-
nant cells. In the early stages of tumorigenesis, TGFβ inhibits
cell growth by inducing apoptosis and arresting the cell cycle.
As cells progress toward a fully malignant tumor phenotype,
they become resistant to the growth-inhibiting effects of TGFβ,
while other TGFβ responses remain fully operative (Roberts
and Wakefield, 2003). At present, the molecular mechanisms
by which cancer cells acquire this selective resistance are un-
clear. Our results indicate that LOI provides one mechanism by
which cells can become resistant to the growth-inhibitory ef-
fects of TGFβ. At least three imprinted genes have been impli-
cated in TGFβ signaling (Tsibris et al., 2002). TSP1 and IGF2R
act as nonsignaling receptors for TGFβ and facilitate the cleav-
age and activation of the latent (preproprotein) ligand (Godar
et al., 1999; Murphy-Ullrich and Poczatek, 2000). LOI-induced
loss of Tsp1 and Igf2r expression, resulting in a failure to pro-
cess latent TGFβ, is unlikely to be responsible for the lack of
TGFβ responsiveness, as IF-MEFs also failed to respond to
active, cleaved ligand. p57 is a more likely candidate, as this
gene encodes a putative tumor suppressor that belongs to the
Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors and
acts as a negative regulator of the cell cycle (Deshpande et al.,
2005). In human hematopoietic cells, p57 is upregulated by
TGFβ and is essential for mediating its cytostatic effects on
blood cells (Scandura et al., 2004). Whether p57 plays a similar
role in MEFs has yet to be determined. A third possibility
comes from the recent discovery that p53 plays a key role in
TGFβ-induced growth arrest (Cordenonsi et al., 2003; Takeba-
yashi-Suzuki et al., 2003). p53−/− MEFs show a defective cyto-
static response to TGFβ and an inability to upregulate the CDK
inhibitor p21WAF1 (Cordenonsi et al., 2003). Furthermore, p53
interacts with Smad2 and Smad3, downstream mediators of
TGFβ signaling, where it appears to function as part of a tran-
scriptional complex (Cordenonsi et al., 2003; Labbe et al.,
2000; Liberati et al., 1999; Seoane et al., 2004). It is tempting
to speculate that the mechanism by which LOI inhibits the
ARF-p53 pathway to immortalize MEFs is related to its ability
to confer resistance to TGFβ-induced growth arrest. Further
study is required to unravel the importance of p53 in LOI-
induced tumorigenesis.
Consistent with LOI rendering MEFs highly susceptible to282transformation, all chimeric mice derived from IF-ES cells de-
veloped tumors in multiple tissues. This suggests that global
LOI has a causal role in promoting cancer. The most common
cancers were hepatocellular carcinomas and intestinal adeno-
mas. It is unclear why this particular spectrum of cancer was
observed in the IF chimera mice. It is possible, however, that
tumorigenesis may be due to the dysregulation of imprinted
tumor suppressor genes and oncogenes specific to each or-
gan. The long latency of tumor development indicates that LOI
sensitizes cells to cancer and that additional somatic events
are required for tumor development. Offspring derived from
chimeric mice that had inherited the ES cell-derived IF genome
were cancer free. This indicates that the aberrant state of ge-
nomic imprinting in the IF-ES cells is fully reversible after pas-
sage through the germline, consistent with the fact that the
methylation associated with imprinting can only be established
in germ cells. If the tumorigenic phenotype in the LOI model
was caused by a random mutational event during ES culture,
then tumors would be expected to also arise in the F1 progeny.
Although it is possible that an oncogene or tumor suppressor
gene may have been improperly methylated (and thereby be-
came abnormally expressed) during the generation of the IF-
ES cells, we would have expected to detect such an abnormal-
ity from the microarray analysis. Furthermore, the likelihood of
such an event occurring in two independently derived IF-ES
cell lines but not the CTL-ES lines is small.
In summary, the ability of a cell to become immortal is a
prerequisite for transformation and ultimately tumor formation.
By manipulating the maintenance methylase Dnmt1, we were
able to generate ES cells that lack the methylation marks re-
quired for maintaining imprinting, leading to global LOI. Our
study provides strong evidence that LOI predisposes cells to
cancer. The data support a model in which LOI at key loci en-
coding tumor suppressors and oncogenes provides the first
step toward tumor formation by conferring cellular immortality.
Furthermore, our results are consistent with subsequent ge-
netic alterations, such as constitutive activation of a mitogenic
signal, providing the next step necessary for a fully trans-
formed phenotype both in vitro and in vivo.
Experimental procedures
2frt-flanked Dnmt1 inactive allele
We constructed an inactive Dnmt1 allele (2frt) by inserting a stop cassette
flanked by two Frt sites between the fourth and fifth coding exons in the
Dnmt1 gene. This allele becomes reactivated following Flp-mediated re-
combination (Figure S1B in the Supplemental Data available with this arti-
cle online).
Generation of IF and control ES cells
All experiments on live vertebrates were performed in accordance with rele-
vant institutional and national guidelines and regulations. Massachusetts
Institute of Technology’s committee on animal care has approved the exper-
iments and has confirmed that all experiments conform to the relevant regu-
latory standards. The most recent review and approval were received on
November 4, 2004.
Mice heterozygous for the inactive 2frt Dnmt1 allele were crossed to mice
homozygous for the conditional 2loxp Dnmt1 allele (Jackson-Grusby et al.,
2001) and the ROSA26-β-geo Flp reporter allele (Possemato et al., 2002).
Fertilized embryos were dissected at E0.5, cultured until the blastocyst
stage, and explanted for ES cell line derivation as described (Hochedlinger
and Jaenisch, 2002). ES cells were cultured as previously described (Li et
al., 1992). Two independently derived ES cell lines tested positive for both
the 2frt and the 2loxp Dnmt1 alleles. These cells were exposed to Cre re-CANCER CELL : OCTOBER 2005
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short-term puromycin selection, positive clones were picked and expanded,
and their genomic DNA was extracted. Clones were analyzed for Cre-medi-
ated recombination of the Dnmt1 (2loxp to 1loxp) allele by Southern blot-
ting. Positive clones were expanded, and the process was repeated with
exposure to Flpe recombinase to excise the stop cassette and reactivate
Dnmt1 expression. The resultant doubly recombined Dnmt1 ES cells were
termed IF (Figure 1). Control ES cells (CTL) were generated by exposure to
the same recombinases but in the reverse order (Figure 1). Genomic DNA
was extracted from ES cells at each stage of recombination for each Dnmt1
genotype, 2loxp/2frt, 1loxp/2frt, 2loxp/1frt, and 1loxp/1frt. Southern blotting
analysis was carried out after methylation-sensitive digestion with HpaII.
Repetitive regions and elements known to be methylated were probed;
these included classic centromeric satellite repeats, IAP, and LINE element
(Biniszkiewicz et al., 2002) (Figure S1C).
Derivation of primary embryonic fibroblast cell lines
from IF- and CTL-ES cells
MEFS were derived from day 13.5 embryos obtained by injecting IF- and
CTL-ES cells into wild-type BDF1 blastocysts and implanted into foster
mothers. IF- and CTL-MEFs derived from chimeric embryos were selected
for two passages with the appropriate antibiotics. MEFs were frozen at pas-
sage 2 or 3 and with the exception of long-term culture were used for all
experiments before passage 6. Only pure populations were used as as-
sayed by genomic Southern blotting or PCR. MEFs and 293T ecotrophic
packaging cell line were grown in DMEM supplemented with 10% FBC, 5
mM glutamine, and penicillin/streptomycin. All the cells used tested nega-
tive for mycoplasma.
Characterization of the methylation and expression
status of IF- and CTL-MEFs
Genomic DNA was extracted from MEFs isolated from different chimeric
fetuses, and methylation analysis of selected imprinted genes was per-
formed by two different methods. Methylation-sensitive enzymatic digestion
followed by Southern blotting was used to probe for Igf2r methylation (Bin-
iszkiewicz et al., 2002). COBRA analysis was used to analyze the methyla-
tion status of Igf2 Snrpn and Peg3 (Lucifero et al., 2002). Expression analy-
sis of selected imprinted genes was carried out by two different methods
using total RNA extracted from different clones of CTL- and IF-MEFs. Ex-
pression of Igf2r, H19, Igf2, Peg5, and Grb10 was analyzed by Northern
blotting using cDNA probes to the open reading frame of these genes. P57,
Peg1, and Peg3 expression was analyzed by RT-PCR using the following
primers: P57, forward CTGACCTCAGACCCAATTCC and reverse GTTC
TCCTGCGCAGTTCTCT; Peg1 forward GCTGGGGAAGTAGCTCAGT and
reverse TTTCTTCTTAGCAAGGGCCA; Peg3 reverse CTTCTGGAAGCCGA
CATTATC and forward CCTGATCAATGGGTTCCTTG; β-actin forward GGT
CAGAAGGACTCCTATGTGG and reverse TCCCTCTCAGCTGTGGTGGT.
Microarray analysis of IF- and CTL-MEFs
Arrays were manufactured from the Mouse Genome Oligo Set V3 (Operon),
which contains 31,769 oligo probes. Oligos were printed onto CodeLink
Activated Slides (Amersham) using an Omnigrid 100 printer (Genemach-
ines). Printing and postprocessing of arrays were carried out according to
the manufacturer’s instructions, using a modified print buffer containing 250
mM phosphate buffer (pH 8.5), with 0.00025% N-Lauroylsarcosine.
For expression profiling, 5 g of total RNA from independent IF-MEF (n =
6) and CTL-MEF (n = 2) populations were reverse transcribed using a T7-
oligo-d(T)-primer (TCTAGTCGACGGCCAGTGAATTGTAATACGACTCACTA
TAGGGCGT21N). Second strand cDNA was synthesized as previously de-
scribed (Gubler and Hoffman, 1983). Double-stranded cDNAs were purified
and in vitro transcribed with the Microarray RNA Target Synthesis Kit T7
(Roche). Unlabeled cRNAs were purified, and 1 g cRNA per channel was
labeled with 1 l Cy5 or Cy3 using the Micromax ASAP RNA labeling kit
(Perkin Elmer). Arrays were hybridized, washed, and dried according to the
Agilent 60-mer oligo microarray processing protocol.
Arrays were scanned with a GenePix400B Scanner (Axon Instruments),
and expression data were extracted by Genepix Pro 6 Software (Axon).
Data normalization within and between arrays was performed with the
Limma software package of the Bioconductor project (Smyth, 2004). Micro-
array data can be found in the Supplemental Data.CANCER CELL : OCTOBER 2005Retroviral infection assay
MEFs were infected with a high titer of retrovirus stocks produced by tran-
sient transfection of 293T cells with an ecotrophic packaging virus. pBabe-
blast or pWZL-blast cells containing the retroviral infection were selected
out with blasticidin. The pBabe-blast and pWZL-blast vectors containing
constitutively active V12H-Ras or LgT cDNA, respectively, were both gifts
of R. Weinberg (The Whitehead Institute).
Immunoblotting
Whole-cell extracts of exponentially growing cells were prepared in lysis
buffer (65 mM Tris [pH 7], 1% NP40, 2 mM EDTA, 100 mM NaCl) containing
the Complete cocktail of protease inhibitors (Roche), and protein concentra-
tions were determined with the BioRad D/C protein assay reagent. Immu-
noblot analysis of p53 (Oncogene, AB-3, 1:500), p16INK4A (Santa Cruz,
M-156, 1:1000), p21CIP1 (Santa Cruz, F-5, 1:1000), and p19ARF (Novus
Biological, AB80-100, 1:500) was performed with 60 µg of proteins run on
12.5% acrylamide gels transferred to Immobilon-P (Millipore). Secondary
antibodies coupled to HRP were purchased from Jackson Immuno-
Research Laboratories and used at 1:10,000. Detection was performed by
chemiluminescence.
Growth curves, immortalization, and transformation assays
All experiments were repeated at least three times using cells from a mini-
mum of five different fetuses for each genotype. For growth curves, 3 × 104
cells were plated into 12-well dishes and fed every second day. Serial 3T3
cultivation was conducted as described. To test the ability of the cells to
form multiple layers (foci formation assay), 1 × 105 cells were plated in
triplicate for each of the different genotypes and grown for 28 days; the
medium was changed every second day. Plates were then fixed in ice-cold
methanol and stained with cresyl violet. Low-density foci assays were con-
ducted by plating 1.3 × 103 MEFs as described (Sage et al., 2000). To test
tumorigenicity, exponentially growing cells were resuspended in PBS, and
1 × 106 cells were injected subcutaneously into SCID mice. Tumor develop-
ment was monitored for up to 6 months. IF- and CTL-MEFs infected with
pBabe V12H-Ras-blasticidin, pBabe-blasticidin, pWZL LgT-blasticidin, and
pWZLGFP-blasticidin were selected for 3 days in 2 g/ml blasticidin and
then replated to be expanded for foci formation assays and injection into
SCID mice.
TGFβ and cell cycle
Cells were plated at 3 × 104 in 12-well plates from six different embryos
for each genotype in triplicate and 24 hr later were exposed to TGFβ at a
concentration of 0.1 nM. Cells were then counted each day for 5 days. Cells
were prepared for cell cycle analysis as described (Brugarolas et al., 1998).
Samples were processed using FACScan apparatus (Becton Dickinson),
and the data were analyzed using ModFit LT software (Becton Dickinson).
Generation of IF chimeric mice and histological analysis
IF and control ES cells were injected into wild-type BDF1 blastocysts.
Chimeric animals were born and allowed to age for the following time
points: 9, 12, and 18 months. Tumors were removed at necropsy from chi-
mera animals and fixed in formalin for sectioning and later stained with H&E.
PCR, RT-PCR, and methylation tumor analysis
Genomic DNA from all tumors was extracted and tested for the presence
of the neomycin gene using the following primers: forward AAGCCGGTCT
TGTCGATCAG and reverse GATATTCGGCAAGCAGGCAT. The methylation
status of genomic DNA associated with IGF2 and IGF2r was assessed by
COBRA, and methylation-sensitive digestion and Southern blotting, respec-
tively (Biniszkiewicz et al., 2002; Lucifero et al., 2002). RNA was extracted
from tumors using the Qiagen RNeasy Kit, and RT-PCR was performed
using the following primer pairs for these genes: Igf2 forward TGCTTCTC
ATCTCTTTGGCC and reverse GGCACAGTATGTCTCCAGGA; Igf2r forward
GTGTGGTATTTTTATGTATAGTTAGG and reverse AAATATCCTAAAAATAC
AAACTACAC; P57 forward CTGACCTCAGACCCAATTCC and reverse GTT
CTCCTGCGCAGTTCTCT; β-actin forward GGTCAGAAGGACTCCTATGTGG
and reverse TCCCTCTCAGCTGTGGTGGT.283
A R T I C L ESupplemental data
The Supplemental Data include one supplemental figure and microarray
data and can be found with this article online at http://www.cancercell.org/
cgi/content/full/8/4/275/DC1/.
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